Stent designs with ultrathin struts may further increase the procedural success of challenging lesion subsets. The objective of this study was to assess the safety and efficacy of ultrathin strut, polymer-free sirolimus eluting stent (PF-SES) implantations in a large scale, unselected patient population.Adult patients underwent percutaneous coronary interventions (PCI) with a thin-strut PF-SES. Data from two all-comers observational studies having the same protocol (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were pooled. The accumulated target lesion revascularization (TLR) rate at 9-12 months was the primary endpoint. All dual antiplatelet therapy strategies according to the applicable guidelines were permissible.In total, 7243 patients were prospectively enrolled for PCI with PF-SES in stable coronary artery disease or acute coronary syndrome (ACS). Major risk factors in the overall cohort were diabetes (37.3%), ST elevation myocardial infarction (18.1%) and non-ST myocardial infarction (24.6%). The follow-up rate was 88.6% in the overall population. The TLR rate in the overall cohort was 2.2% whereas definite/probable stent thrombosis (ST) occurred in 0.7%. In patients with in-stent restenosis lesions, the major adverse cardiac events rate was 6.4% whereas the corresponding rate for isolated left main coronary artery (LMCA) disease was highest with 6.7% followed by patients with culprit lesions in vein bypasses (VB, 7.1%). The mortality rate in patients treated in VB lesions was highest with 5.4%, followed by the isolated LMCA subgroup (3.4%) and ACS (2.6%).PCI with PF-SES in an unselected patient population, is associated with low clinical event and ST rates. Furthermore, PF-SES angioplasty in niche indications demonstrated favorable safety and efficacy outcomes with high procedural success rates.

Centre Hospitalier d'Avignon Avignon France

Chonnam National University Gwangju

Clinique du Millénaire Montpellier

Clinique Turin Paris

Daegu Fatima Hospital

Department of Internal Medicine and Cardiology Charité Universitätsmedizin Berlin Campus Virchow Klinikum Berlin

Gachon University Gil Medical Center Incheon

Hôpital Albert Schweitzer Colmar

Hospital General Universitario de Ciudad Real Ciudad Real

Hospital Universitari Germans Trias i Pujol Badalona Spain

Hospital Universitari Vall d'Hebron

Hospital Universitario de Cruces Bilbao

IKEM Prague Czech Republic

Kangdong Sacred Heart Hospital South Korea

Medical Scientific Affairs B Braun France Saint Cloud France

Medical Scientific Affairs B Braun Melsungen AG Berlin Germany

Pantai Ayer Keroh Hospital Malaysia

Städtische Kliniken Esslingen Esslingen Germany

SÚSCCH a s Banská Bystrica Slovak Republic

University Hospital Královské Vinohrady Prague Czech Republic

Zobrazit více v PubMed

Yamaji K, Zanchin T, Zanchin C, et al. Unselected use of ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for coronary revascularization. Circ Cardiovasc Interv 2018;11:e006741. PubMed

Maeng M, Christiansen EH, Raungaard B, et al. SORT OUT VIII investigators. Everolimus-eluting versus biolimus-eluting stents with biodegradable polymers in unselected patients undergoing percutaneous coronary intervention: a randomized noninferiority trial with 1-year follow-up (SORT OUT VIII Trial). JACC Cardiovasc Interv 2019;12:624–33. PubMed

Krackhardt F, Kočka V, Waliszewski MW, et al. Polymer-free sirolimus-eluting stents in a large-scale all-comers population. Open Heart 2017;4:e000592. PubMed PMC

Krackhardt F, Rosli MA, Leschke M, et al. Propensity score matched all comers population treated with ultra-thin strut bare metal and sirolimus-probucol coated drug-eluting stents of identical stent architecture. Catheter Cardiovasc Interv 2018;91:1221–8. PubMed

Sperling C, Waliszewski MW, Kherad B, et al. Comparative preclinical evaluation of a polymer-free sirolimus-eluting stent in porcine coronary arteries. Ther Adv Cardiovasc Dis 2019;13:1753944719826335. PubMed PMC

Cutlip DE, Windecker S, Mehran R, et al. Academic research consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344–51. PubMed

Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials. Circulation 2011;123:2736–47. PubMed

Thygesen K, Alpert JS, Jaffe AS, et al. Joint ESC/ACCF/AHA/WHF task force for universal definition of myocardial infarction, authors/task force members chairpersons, biomarker subcommittee, ECG subcommittee, imaging subcommittee, classification subcommittee, intervention subcommittee, trials & registries subcommittee, trials & registries subcommittee, trials & registries subcommittee, trials & registries subcommittee, ESC committee for practice guidelines (CPG), document reviewers. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581–98. PubMed

Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European society of cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS) developed with the special contribution of the European association of percutaneous cardiovascular interventions (EAPCI). Eur Heart J 2014;35:2541–619. PubMed

Wöhrle J, Zadura M, Möbius-Winkler S, et al. SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol 2012;60:1733–8. PubMed

Leschke M, Waliszewski M, Pons M, et al. A. Thin strut bare metal stents in patients with atrial fibrillation: is there still a need for BMS? Catheter Cardiovasc Interv 2016;88:358–66. PubMed

Tadano Y, Kotani JI, Kashima Y, et al. Predictors of clinical outcomes after coronary implantation of bioresorbable polymer sirolimus-eluting Ultimaster stents in all-comers: A report of 1,727 cases. Catheter Cardiovasc Interv 2019. PubMed

Hicks KA, Temple RJ. The devil is always in the details. JACC Cardiovasc Interv 2017;10:667–71. PubMed

Alfonso F, Antuña P. New-generation drug-eluting stents for unselected patients with left main coronary artery disease: crossing a second Rubicon? Int J Cardiol 2019;280:49–50. PubMed

Fajadet J, Capodanno D, Stone GW. Management of left main disease: an update. Eur Heart J 2019;40:1454–66. PubMed

Tanaka A, Giustino G, Briede I, et al. DELTA 2 Investigators. New-generation drug-eluting stents for left main coronary artery disease according to the EXCEL trial enrollment criteria: insights from the all-comers, international, multicenter DELTA-2 registry. Int J Cardiol 2019;280:30–7. PubMed

Yoon YH, Lee PH, Ahn JM, et al. IRIS-MAIN registry investigators. Long-term trends of treatment effect of stenting or bypass surgery in patients with ostial or shaft left main coronary artery disease. Catheter Cardiovasc Interv 2019;94:315–22. PubMed

Andrade PJN, Falcão JLAA, Falcão BAA, et al. Stent versus coronary artery bypass surgery in multi-vessel and left main coronary artery disease: a meta-analysis of randomized trials with subgroups evaluation. Arq Bras Cardiol 2019;112:511–23. PubMed PMC

Panoulas VF, Ilsley CJ, Kalogeras K, et al. Coronary artery bypass confers intermediate-term survival benefit over percutaneous coronary intervention with new-generation stents in real-world patients with multivessel coronary artery disease, including left main disease: a retrospective analysis of 6383 patients. Eur J Cardiothorac Surg 2019;56:911–8. PubMed

De Rosa S, Polimeni A, Sabatino J, et al. Long-term outcomes of coronary artery bypass grafting versus stent-PCI for unprotected left main disease: a meta-analysis. BMC Cardiovasc Disord 2017;17:240. PubMed PMC

Baan J, Jr, Claessen BE, Dijk KB, et al. A Randomized comparison of paclitaxel-eluting balloon versus everolimus-eluting stent for the treatment of any in-stent restenosis: the DARE trial. JACC Cardiovasc Interv 2018;11:275–83. PubMed

Alfonso F, Pérez-Vizcayno MJ, Cuesta J, et al. RIBS IV study investigators (under the auspices of the interventional cardiology working group of the spanish society of cardiology). 3-year clinical follow-up of the RIBS IV clinical trial: a prospective randomized study of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis in coronary arteries previously treated with drug-eluting stents. JACC Cardiovasc Interv 2018;11:981–91. PubMed

Garg A, Rout A, Tayal R, et al. Drug-eluting stents versus bare-metal stents for saphenous vein graft interventions: a systematic review and meta-analysis of studies with longer follow-up. Curr Probl Cardiol 2019. PubMed

Hall AB, Brilakis ES. Treating saphenous vein graft lesions: drug-eluting stents are not the answer!. Catheter Cardiovasc Interv 2019;93:E193–4. PubMed

Shah R, Jovin IS, Latham SB, et al. A comprehensive meta-analysis of randomized controlled trials comparing drug-eluting stents with bare-metal stents in saphenous vein graft interventions. Catheter Cardiovasc Interv 2018;92:1229–36. PubMed

Brilakis ES, Edson R, Bhatt DL, et al. Banerjee S; DIVA trial investigators. Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial. Lancet 2018;391:1997–2007. PubMed PMC

Moalem K, Baber U, Chandrasekhar J, et al. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. Clin Res Cardiol 2019;108:643–50. PubMed

Zobrazit více v PubMed

ClinicalTrials.gov
NCT02629575, NCT02905214